Analysts’ updated eps estimates for Tuesday, December 10th:
Apple (NASDAQ:AAPL) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $260.00 price target on the stock.
AbbVie (NYSE:ABBV) had its neutral rating reaffirmed by analysts at Bank of America Co.. Bank of America Co. currently has a $191.00 price target on the stock.
Arcellx (NASDAQ:ACLX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $115.00 price target on the stock.
Acurx Pharmaceuticals (NASDAQ:ACXP) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $12.00 price target on the stock.
Affimed (NASDAQ:AFMD) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $10.00 price target on the stock.
C3.ai (NYSE:AI) had its hold rating reissued by analysts at Needham & Company LLC.
Amgen (NASDAQ:AMGN) had its underperform rating reaffirmed by analysts at Bank of America Co.. They currently have a $256.00 target price on the stock.
Amazon.com (NASDAQ:AMZN) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $250.00 price target on the stock.
AngioDynamics (NASDAQ:ANGO) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $14.00 target price on the stock.
Artivion (NYSE:AORT) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $33.00 price target on the stock.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $2.00 price target on the stock.
Astria Therapeutics (NASDAQ:ATXS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $16.00 target price on the stock.
Atyr PHARMA (NASDAQ:ATYR) had its buy rating reissued by analysts at HC Wainwright. They currently have a $35.00 price target on the stock.
Biogen (NASDAQ:BIIB) had its neutral rating reiterated by analysts at Bank of America Co.. The firm currently has a $178.00 target price on the stock.
Biomea Fusion (NASDAQ:BMEA) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $128.00 target price on the stock.
Biomea Fusion (NASDAQ:BMEA) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $40.00 target price on the stock.
Bristol-Myers Squibb (NYSE:BMY) had its neutral rating reissued by analysts at Bank of America Co.. Bank of America Co. currently has a $63.00 target price on the stock.
Braze (NASDAQ:BRZE) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $50.00 target price on the stock, down from their previous target price of $70.00.
Braze (NASDAQ:BRZE) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc.. The firm currently has a $51.00 target price on the stock.
BrightSphere Investment Group (NYSE:BSIG) had its sector perform rating reissued by analysts at BMO Capital Markets. BMO Capital Markets currently has a $33.00 price target on the stock, up from their previous price target of $30.00.
Cross Country Healthcare (NASDAQ:CCRN) had its market perform rating reiterated by analysts at Barrington Research.
Ciena (NYSE:CIEN) had its buy rating reissued by analysts at Stifel Nicolaus. They currently have a $82.00 target price on the stock, up from their previous target price of $75.00.
Clene (NASDAQ:CLNN) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $23.00 price target on the stock.
Costco Wholesale (NASDAQ:COST) had its outperform rating reiterated by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $1,075.00 price target on the stock, up from their previous price target of $980.00.
Curis (NASDAQ:CRIS) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $20.00 price target on the stock.
CRISPR Therapeutics (NASDAQ:CRSP) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $94.00 target price on the stock.
CervoMed (NASDAQ:CRVO) had its hold rating reissued by analysts at D. Boral Capital.
DBV Technologies (NASDAQ:DBVT) had its market outperform rating reiterated by analysts at JMP Securities. They currently have a $10.00 target price on the stock.
Quest Diagnostics (NYSE:DGX) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $185.00 price target on the stock, up from their previous price target of $175.00.
First American Financial (NYSE:FAF) had its market perform rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $80.00 target price on the stock.
Four Corners Property Trust (NYSE:FCPT) had its market perform rating reiterated by analysts at JMP Securities.
Geron (NASDAQ:GERN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $9.00 target price on the stock.
G-III Apparel Group (NASDAQ:GIII) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. The firm currently has a $32.00 target price on the stock.
Gilead Sciences (NASDAQ:GILD) had its buy rating reissued by analysts at Bank of America Co.. The firm currently has a $109.00 price target on the stock.
Alphabet (NASDAQ:GOOGL) had its outperform rating reaffirmed by analysts at Robert W. Baird. They currently have a $205.00 price target on the stock.
Hershey (NYSE:HSY) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $183.00 target price on the stock.
Imunon (NASDAQ:IMNN) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $29.00 target price on the stock.
Iris Energy (NASDAQ:IREN) had its neutral rating reissued by analysts at JPMorgan Chase & Co.. The firm currently has a $15.00 target price on the stock, up from their previous target price of $9.50.
Jacobs Solutions (NYSE:J) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. The Goldman Sachs Group, Inc. currently has a $150.00 price target on the stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $179.00 price target on the stock.
Johnson & Johnson (NYSE:JNJ) had its neutral rating reiterated by analysts at Bank of America Co.. The firm currently has a $166.00 target price on the stock.
Krystal Biotech (NASDAQ:KRYS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $221.00 price target on the stock.
LandBridge (NYSE:LB) had its underperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $25.00 target price on the stock.
Legend Biotech (NASDAQ:LEGN) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $73.00 price target on the stock.
Laboratory Co. of America (NYSE:LH) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $275.00 target price on the stock, up from their previous target price of $265.00.
Eli Lilly and Company (NYSE:LLY) had its buy rating reissued by analysts at Bank of America Co.. The firm currently has a $997.00 price target on the stock.
Liquidity Services (NASDAQ:LQDT) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $27.00 target price on the stock.
MongoDB (NASDAQ:MDB) had its buy rating reissued by analysts at Truist Financial Co.. They currently have a $400.00 target price on the stock, up from their previous target price of $320.00.
MongoDB (NASDAQ:MDB) had its overweight rating reissued by analysts at Piper Sandler. The firm currently has a $425.00 target price on the stock.
Merck & Co., Inc. (NYSE:MRK) had its buy rating reaffirmed by analysts at Bank of America Co.. The firm currently has a $121.00 price target on the stock.
Moderna (NASDAQ:MRNA) had its underperform rating reissued by analysts at Bank of America Co.. The firm currently has a $41.00 price target on the stock.
MGIC Investment (NYSE:MTG) had its market perform rating reaffirmed by analysts at Keefe, Bruyette & Woods. The firm currently has a $29.00 price target on the stock.
NOV (NYSE:NOV) had its sector perform rating reiterated by analysts at ATB Capital. The firm currently has a $19.00 target price on the stock.
Nurix Therapeutics (NASDAQ:NRIX) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $29.00 target price on the stock.
Novavax (NASDAQ:NVAX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $19.00 price target on the stock.
Oracle (NYSE:ORCL) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $205.00 target price on the stock.
PagSeguro Digital (NYSE:PAGS) had its neutral rating reaffirmed by analysts at Bank of America Co..
Pfizer (NYSE:PFE) had its neutral rating reissued by analysts at Bank of America Co.. Bank of America Co. currently has a $29.00 target price on the stock.
Phreesia (NYSE:PHR) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $29.00 target price on the stock.
Phreesia (NYSE:PHR) had its market outperform rating reissued by analysts at JMP Securities. They currently have a $30.00 target price on the stock.
Pinterest (NYSE:PINS) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $48.00 price target on the stock.
Planet Labs PBC (NYSE:PL) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $5.00 price target on the stock.
Protagonist Therapeutics (NASDAQ:PTGX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $50.00 price target on the stock.
Pactiv Evergreen (NASDAQ:PTVE) had its neutral rating reissued by analysts at Citigroup Inc.. They currently have a $18.00 target price on the stock, up from their previous target price of $13.00.
Qiagen (NYSE:QGEN) had its buy rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a $54.00 price target on the stock, up from their previous price target of $42.00.
uniQure (NASDAQ:QURE) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $25.00 price target on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) had its underperform rating reaffirmed by analysts at Bank of America Co.. The firm currently has a $565.00 target price on the stock.
Rent the Runway (NASDAQ:RENT) had its market outperform rating reaffirmed by analysts at JMP Securities. They currently have a $40.00 price target on the stock.
Rigel Pharmaceuticals (NASDAQ:RIGL) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $57.00 target price on the stock.
Rocket Companies (NYSE:RKT) had its underperform rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $11.50 price target on the stock, down from their previous price target of $16.00.
Sangamo Therapeutics (NASDAQ:SGMO) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $10.00 price target on the stock.
Silence Therapeutics (NASDAQ:SLN) had its buy rating reiterated by analysts at Chardan Capital. They currently have a $55.00 target price on the stock.
Syndax Pharmaceuticals (NASDAQ:SNDX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $51.00 price target on the stock.
Stoke Therapeutics (NASDAQ:STOK) had its overweight rating reiterated by analysts at Cantor Fitzgerald.
Sutro Biopharma (NASDAQ:STRO) had its outperform rating reiterated by analysts at Wedbush. They currently have a $8.00 price target on the stock.
VolitionRx (NYSE:VNRX) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $5.00 price target on the stock.
Vor Biopharma (NYSE:VOR) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $17.50 target price on the stock.
Vor Biopharma (NYSE:VOR) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $12.00 target price on the stock.
Whitestone REIT (NYSE:WSR) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $16.00 price target on the stock.
Solitario Resources (NYSEAMERICAN:XPL) (TSE:SLR) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $1.20 target price on the stock.
Yext (NYSE:YEXT) had its buy rating reiterated by analysts at Roth Mkm. They currently have a $10.50 price target on the stock, up from their previous price target of $7.50.
Zeta Global (NYSE:ZETA) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $43.00 price target on the stock.
Zeta Global (NYSE:ZETA) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $43.00 price target on the stock.
Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.
